Member Info for olderbutwiser

Been at the top since about 9am
https://uk.advfn.com/
Looking for a few 15% and 20% rises here over next days - do not forget that US markets are closed today - Thanksgiving - so tomorrow could be good rise pm.
Putting out the news on Thanksgiving day - is this a coded message from the bod that great things are coming?

Fair comment ForFXSake - I must have misread your post.

Personally I do not want Allenby's clients to buy - they were shown to be a bunch of rampers and short termers just out for a quick buck .
Quite happy if they stay out.
The rerate will happen over next few days and weeks.
Anyway we only see trades they want us to see - could be lots going on unseen.

No one has said the durability test is 'immaterial to deal-making' apart from you ForFXSake. I said the durability testing was a 'comparatively low risk' (compared to the tests already successfully completed) and I have not mentioned any link to deal-making.
Obviously we want to/ need to pass the durability test.

'You would have thought Allenby would have had their clients primed for today's news release'.
That would have been insider dealing if Allenby were informed of RNS ahead of 7am today.
Recent days trading shows there was no leak to anybody.

Logically they tackled the NXP002 tests with the highest risk tests being done first - so I assume that durability testing (Accelerated ageing - shelf life studies, etc) is comparatively low risk.

Nuformix have now announced NXP004 successful patent filing and NXP002 successful trial results (with durability to come).
They have said that they would approach potential new CEO's only once they had success for both 002 and 004 - perhaps they have someone lined up and that is reason for sudden release of RNS today?

Feel this is the start of the rerate.
No doubt there will be the usual 10% sellers who have no idea what deals could be on the way and will miss out on the fantastic gains to be made here over the coming weeks.

Excellent news.But why release it now when only a week ago they seemed to be saying no news on NXP002 results until January 2022 when the final durability tests are completed?What has changed?Is a potential lincensee very interested and negotiations in the offing? Or are they just responding to investor concerns about delay?Wonderful news - think could be something interesting happening behind the scenes for this sudden release of news.GLA

Perhaps you should include deductions for any toilet breaks too! LOL

ForFXSake - You may well be right, it was a vague statement – but it seems very common in pharma companies for 'full-time' directors to have NED/ consultant/ scientific advisor positions in other companies which typically involve only a very few days a year of input.
That they are talking to potential licensees (more than one) presumably means the originator and one or more generic companies. With several companies interested in your IP the true value is more likely to be offered and it will incentivise the interested parties to show their commitment as soon as possible.

18-Nov-21 16:36:23 26.1875 300,000 Buy* 25.50 26.00 78.56k

Anne's plan has been the way forward since march and the totally new bod are all behind it.
We are about to reap some of the rewards of that plan.
I am hoping that Alistair's vague comments about keeping an association with Anne after January 2022 will become tangible with her possibly becoming a NED, or having some sort of ad hoc consultant role - something that provides some access to her expertise when required. I am assuming he would not have mentioned it at all in such an interview unless there had already been some concrete discussions with Anne.
We will see.

Short answer TAZ is that it will.
The recent RNS for NXP004 was a massive success for the company and kick-starts negotiations with potential licensees. So with most pharma’s you would indeed usually see a significant upwards move on such news.
There are many potential reasons – past performance issues, pharma sector sell off, CEO concerns, etc.
However we all know that there are often big disconnects between a companys potential value and its sp - which is one of the aspects that make up the financial markets – the markets are often wrong, which is what contrarian investors rely on. Also the markets over-price on the way up and under-price on the way down.
Obviously it will be an amalgam of many aspects.
We were at 2.8p last Xmas when Nuformix was in a dire situation and now priced at 1.5p with all the new and imminent potential – says it all really.
Anyway I think we are massively in the under-valued category and it is just a matter of when the correction occurs. With latest RNS I think it should be very soon.
Just my ramblings on a slow morning.
GLA

I do not want the company doing any research on potential new drugs. I want them to concentrate on licensing and monetising what they already have and only doing any supporting research for that purpose. This has been Anne’s strategy from when she joined.
We now have a license agreement for NXP001 oncology use.
We still have potential to out-license NXP001 for other uses.
We are within a couple of months of potentially triggering license discussions for NXP002 – our lead drug candidate and worth 9p-per-share on its own.
As of a week ago we are now starting to talk to potential licensees (more than one) about NXP004 – this potentially offers the originator a huge patent life extension plus the opportunity for multiple improvements to their £billion -a-year oncology drug which is close to losing its patent protection. The value of NXP004 to the originator is potentially huge (£10billion or so) and therefore if the originator offers just a small percent of that to Nuformix it would be mega bucks (1% would be £100m). I believe they will snap our arm off and pay big bucks for the privilege, and if they don’t somebody else, almost certainly, will. I also think Nuformix will be in a better negotiating position with NXP004 and will be able to relatively quickly drive a good deal.
Once we have monetized something substantial - and I think we are getting quite close - then we might contemplate new research but at the moment it is pointless and just takes money away from the current task of licensing/ monetising.
Conversely a deal for either NXP004 or NXP002 might involve Nuformix being bought out at many times its current value, which would potentially be a good out for all involved (including JH and DG) – in which case further research is again pointless.
The company is in a much stronger position than when Anne joined us - is funded up to end of 2022/ early 2023 and we are now negotiating licensing for NXP004 and about to trigger negotiations for licensing of NXP002 in just a couple of months.
Go figure!

Anne mentions potentially carrying out some further research work to supplement the latest patent filing using the CRO.
Even seemed to suggest that closing their Cambridge laboratory does not preclude other future research using the outsourced CRO approach.

Jiving - last fridays RNS about filing NXP004 patent was the one - for obvious reasons they will not tell us specifics about the results as they are sensitive.
In interview Anne told us the new patent was a second family of cocrystals of the originator drug - so with the first 004 patent last year that makes two families of cocrystals of the originator drug that we have now patented - both with benefits over the originator drug.
They will now talk to potential licensees.
So great news we have key IP related to improving and extending the future sales of a £billion oncology drug.
Soup gave an indication of potential value a few weeks ago - could well be immense value to Nuformix.

Riddell mentioned possibly keeping an association with Anne after she leaves the company!
What form that may take - consultant or NED or something else - was not stated.
Definitely be a good thing to do and to me shows that Anne and Alistair really do have very good results for NXP004 and NXP002.

I think Anne mentioned that can now talk to potential licensees.
Using the plural

Generally positive update on what has been already released RNS's. Gave marginally better insight into the potential benefits of the new cocrystal form over the originator drug - there seem to be many very worthwhile benefits for it to be attractive to the current £billion originator company as well as increasing their patent protection for a further 10 years, so looks very promising for negotiations.
Shame about the slight delay to NXP002 research data - would have been nice to have in the remaining 4 weeks before xmas just have to wait a little bit longer for the right result in January .
GLA